human
-
The genetic 'gray area' of Huntington's disease: what does it all mean?
Intermediate alleles and reduced penetrance – the genetic 'gray area' of Huntington’s disease, explained
-
Dimebon fails in late-stage human HD clinical trial
Dimebon fails to improve symptoms in HD patients in the HORIZON trial
-
FDA: further trial needed for Huntexil approval in HD
Bad news for Huntexil – the FDA requires another trial before it can be approved in the US
-
Successful gene therapy trial in Parkinson’s Disease gives hope for HD
Success for brain ‘gene therapy’ in Parkinson’s disease – good news for similar treatments being developed in HD
-
An active lifestyle may make a difference to HD symptoms
More reasons to be active: a passive lifestyle may contribute to earlier onset of symptoms in HD.
-
Dimebon: disappointing in Alzheimer’s but might work in HD
Dimebon – disappointing results in an Alzheimer’s disease trial, but hope remains for HD.
-
Does HD cause brains to develop differently?
Smaller total brain volumes in male HD mutation carriers suggests brain development may be different in HD.
-
Huntexil for symptoms of Huntington's disease: where are we now?
Two clinical trials in Europe and the USA have suggested a new drug, Huntexil, might improve movements in HD. The nex
-
Minocycline: the end of the road?
DOMINO clinical trial result: minocycline doesn’t slow down HD and shouldn’t be studied in larger trials.
-
TRACK-HD reveals significant changes in pre-symptomatic HD mutation carriers and patients
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers